Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

Phase II Investigational Trial Published in CANCER: the Journal of the

American Cancer Society

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today that results of a phase II clinical study, published in the journal CANCER demonstrate that the addition of radioimmunotherapy (RIT) to chemotherapy for previously untreated patients with non-follicular indolent non-Hodgkin's lymphoma (NHL) was both well tolerated and effective, producing a 100 percent complete remission at end of treatment with an estimated 89 percent of patients remaining in remission at three years.

The study, conducted at the Institute of Hematology and Medical Oncology at University of Bologna, Italy, investigated the use of a single dose of Zevalin(R) (Ibritumomab Tiuxetan) as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone (FM chemotherapy) among 26 patients with newly diagnosed non-follicular indolent NHL. Non-follicular lymphomas are also referred to as intermediate grade compared to the low grade follicular or high grade diffuse B cell variety. FM chemotherapy resulted in 50 percent of patients achieving a complete remission (CR) and 30 percent achieving a partial remission (PR). Of the 20 patients (13 with CR and 7 with PR) who were evaluable for Zevalin consolidation, 100 percent obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The most common greater than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 patients).

"This single arm, non-randomized phase II trial provides addition
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , a ... announced today that T. (Teo) Forcht Dagi , ... company,s Board of Directors. " Teo Forcht ... in neurosurgery, medical innovation and venture capital," said Remis ... delighted to add his clinical, strategic, and entrepreneurial expertise to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... stimulants combined provide greater improvement in symptoms ... Addrenex Pharmaceuticals, Inc. today announced positive results ... Clonicel demonstrating that the combination of Clonicel ... in attention deficit hyperactivity disorder (ADHD) symptoms ...
... After a review of several vendors, the University ... selected the services of Velos and its flagship product, ... implemented at UCLA,s Jonsson Comprehensive Cancer Center and an ... Plans are in place to deploy the system in ...
Cached Medicine Technology:Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:8/29/2014)... yoga month was created by the Yoga Health Foundation ... To support this Ekhart Yoga is offering those interested ... This 4 week guided online yoga program is especially ... regularly from their own home. Led by Esther Ekhart, ... all levels, and the dynamic classes will help build ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Senior ... of operations & business development. , Rees has been ... president of business development. , A wholly owned subsidiary ... Independence provides older adults with options, including personalized home ... care (e.g., meal preparation) and therapeutic adult day centers. ...
(Date:8/29/2014)... University of Houston Graduate College of Social Work is the ... million grant from the National Institute of Drug Abuse (NIDA) ... long-term use and health consequences of heroin use. Additionally, the ... future research endeavors. , Heroin use has increased ... prescription pain medication abuse to the cheaper and more available ...
(Date:8/29/2014)... 2014 Last week, the Fed reported ... monthly gain. Industrial production rose to 0.4% while manufacturing output ... is the single largest boost since February this year. Capacity ... since February as well – an increase that could be ... to a 79.2% rate, which is a measure of slack ...
(Date:8/29/2014)... R.I. (PRWEB) August 29, 2014 A home should ... crop up if unaddressed. That’s why Amica Insurance is sharing some ... National Safety Council suggests taking the following safety measures: , Kitchen, ... disinfectants – in their original containers, and keep them away from ... a wall bracket near an exit. , Bathroom , ...
Breaking Medicine News(10 mins):Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Improve Home Safety with Tips from Amica Insurance 2
... Over Estimated,A UK doctor, and a leading expert warned ... are being overstated, leading to unnecessary panic. // ... Tyne said there was very little evidence suggesting that ... nut allergies had saved lives. ,Writing in ...
... A team from the Medical Research Council suggests that ... triggered by the presence of a hormone in semen.// ... the development of tumors. ,In a report in ... recommend that women having either cancer should ask their ...
... night’s sleep is critical to doing well in school because ... in class and while doing homework.// While this is common ... can be complex; and the rewards for treatment can extend ... be getting a good night’s sleep is that he or ...
... cases in Africa as of last year hover around ... Nations //.The World Health Organization has suggested an intelligent ... ,The WHO has advised that the ... Africa could be used to give an impetus to ...
... emergency unit is said to make patients wait longer than ... ,This news has only added salt to the ... procedures at the ERI following its branding as one of ... ,Recent figures have shown that more than a third of ...
... government today introduced a controversial licensing scheme. According to ... will be permitted to describe the ailments they claim ... aim to bring homeopathic remedies into the area of ... doctors and scientists believe that products with no scientific ...
Cached Medicine News:Health News:Inordinately Long Waiting Times at A&E Infirmary 2Health News:Doctors worried about Homeopathic licensing 2
... be used only with the E3671 twisted snare ... the wing nut and the loop can be ... ratchet so that the loop can be slipped ... length - 5.6 inches. Comes with one package ...
Open 14 mm fixation ring with teeth to prevent damage to conjuctiva. Gauge is marked every 10 degrees to determine the extent of the arc to be incised. Two broad marks align with steep axis....
... Titanium. Designed to fixate the ... The two-sided ring can easily ... pointed or smooth side on ... pressure to the eye to ...
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Medicine Products: